Platelet-derived TGF-β and platelet-tumor cell interaction activate the TGF-β and nuclear factor kappa light chain enhancer of activated B cells (NF-κB) pathways in cancer cells, resulting in EMT phenotype and enhanced metastasis in vivo. This evidence concerns the gene TGFB1 and neoplasm.